CD2665 is a selective retinoic acid receptor (RAR)β and RARγ antagonist (K_ds = 110, 306, and > 2,250 nM for RARγ, RARβ, and RARα, respectively, with no binding at RXRα).¹ At 10^-7 M, it has been used to abrogate retinoic acid (Item No. 11017)-induced antiproliferative and antidifferentiative effects on sebocyte growth.¹ This compound has been used in animal and in vitro cell models to explore the role of retinoid signaling in a number of biological processes including memory formation and tumor proliferation.^2,3

≥98%

Store at -20℃

1.Kim, M.J.,Ciletti, N.,Michel, S., et al. The role of specific retinoid receptors in sebocyte growth and differentiation in culture. Journal of Investigative Dermatology 114, 349-353 (2000).

2.Alfos, S.,Boucheron, C.,Pallet, V., et al. A retinoic acid receptor antagonist suppresses brain retinoic acid receptor overexpression and reverses a working memory deficit induced by chronic ethanol consumption in mice. Alcholism: Clinical and Experimental Research 25(10), 1506-1514 (2001).

3.Marikar, Y.,Wang, Z.Q.,Duell, E.A., et al. Retinoic acid receptors regulate expression of retinoic acid 4-hydroxylase that specifically inactivates all-trans retinoic acid in human keratinocyte HaCaT cells. Journal of Investigative Dermatology 111(3), 434-439 (1998).